Wilky called engineered T cells “incredibly exciting” therapies, for the right patients with synovial sarcomas. But she tempered this enthusiasm by cautioning that identifying eligible patients is a challenge. Adaptimmune is now running https://adprun.net/ a pivotal Phase 2 trial , called SPEARHEAD-1, to further evaluate ADP-A2M4 in people with synovial sarcoma. Results may support an application to regulatory authorities requesting the treatment’s approval for this indication.
Treasury yields helped lift expensive stocks in sectors such as technology as investors attempt to gauge the path of inflation. Among the 11 major S&P sectors, technology advanced about 2% as the best performing on the session, as yields on the benchmark 10-year Treasury bond hit a two-week low, which also buoyed other richly-valued growth stocks.
And in 16 patients treated with T cells targeting MAGE-A4, 44% responded and 50% achieved stable disease, according to Brian Van Tine, MD, PhD, of Washington University in St. Louis. Among 45 patients treated with letetresgene autoleucel, 33% responded to the NY-ESO-1-targeting agent, including one complete response, while another 55.5% achieved stable disease, reported Sandra D’Angelo, MD, of Memorial Sloan Kettering Cancer Center in New York City. Tagged Adaptimmune Therapeutics, ADP-A2M4, clinical trial, SPEARHEAD-1 Phase 2 trial, synovial sarcoma, T cell.
More On This News Release
The Company’s unique SPEAR® T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s unique SPEAR® T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. ADP-A2M4, an investigational therapy that uses engineered immune cells to fight cancer, showed an acceptable safety profile and promising effectiveness in people with synovial sarcoma, a rare cancer that develops around the joints and tendons, new clinical trial data show. “This study is a nice proof of concept for treating solid tumours and suggests there could be a role for cellular therapies in these indications going forward.” ‘The impact on patients treated with ADP-A2M4 is transformative, as they benefit from a durable response from a single treatment.
Forty-four percent of patients had confirmed partial response to treatment per RECIST criteria, and 95% had disease control. T-cells are a type of immune cell that have the capacity to kill cancer cells. ADP-A2M4 is an autologous T-cell therapy, a form of treatment in which a patient’s own T-cells are collected, engineered to make them better at killing cancer, and then returned to the patient. Specifically, ADP-A2M4 involves T-cells with an engineered T-cell receptor that targets the cancer-associated protein MAGE-A4. Among 38 patients treated on the trial, the ADP-A2M4 T cells resulted in overall response , or tumour shrinkage, in 9 patients (23.7%) and stable disease in 18 patients (47.4%). In addition to sarcomas, ADP-A2M4 is being investigation in melanoma, head and neck, urothelial, gastric, ovarian, and lung cancers.
- However, much work needs to be done to fully harness the utility of molecular profiling and adopting a truly “personalized medicine” approach for such patients.
- Meanwhile, stocks globally struggled for momentum as investors awaited key US inflation readings for guidance on monetary policy.
- Unfortunately, PARPi resistance has proved to be a major problem in the clinic.
- Some software, such as your security programs, will also affect response time.
- A lack of stats and lower trading volumes will leave the markets to fret over inflation.
- Dominating the bottom of the rankings and dragging on the index, however, were miners including Fresnillo, Antofagasta, BHP and Evraz.
“From cinemas to restaurants, shops to bingo halls, real life has translated into share gains for companies like Primark owner Premier Foods, The Restaurant Group and the Rank Group.” The domestically-focused FTSE 250 index added 84.31 points to close at 22,483. Gambling company Rank Group led the leaderboard, rising 14.2p to 196.2p, followed by Mr Kipling’s parent Premier Foods, which gained 6p to 107.6p. Joining them in the top 10 was Frankie & Benny’s owner The Restaurant Group, which added 6.4p to 128.4p, as well as pub chain Wetherspoon. Similar types of blue-chip companies helped push the FTSE 100 to close in positive territory, though gains were tempered by miners which mostly fell after China’s commodity price warnings. Meanwhile, stocks globally struggled for momentum as investors awaited key US inflation readings for guidance on monetary policy.
Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club. “Data from this trial have enabled rapid execution of our pivotal trial, SPEARHEAD-1, and support our aim to commercialize ADP-A2M4 as the first engineered TCR T-cell product in the US in 2022,” said Adrian Rawcliffe, CEO of Adaptimmune. Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Unlikechimeric antigen receptor -modified T cells, which target surface proteins on cancer cells, TCR T-cell therapies are able to target proteins normally found inside the cell by recognizing protein fragments bound to immune-related proteins on the cell surface. “Data from this trial have enabled rapid execution of our pivotal trial, SPEARHEAD-1, and support our aim to commercialize ADP-A2M4 as the first engineered TCR T-cell product in the US in 2022,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. “However, this is only the beginning of the tremendous potential of our products targeting MAGEA4. We will rapidly pursue additional indications, starting with the Phase 2 trial in gastroesophageal cancers with ADP-A2M4CD8 expected to initiate in the first half of 2021.” “Data from this trial have enabled rapid execution of our pivotal trial, SPEARHEAD-1, and support our aim to commercialize ADP-A2M4 as the first engineered TCR T-cell product in the US in 2022,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. Patients had a median age of 32 years (range 11-73), most were white (87%), and all had received prior systemic therapy. Three of the four cohorts included patients with high NY-ESO-1 expression (immunohistochemistry score of 2+ or 3+ in at least 50% of tumor cells), and one cohort included patients with lower expression. Immuno-Oncology News is strictly a news and information website about the disease.
The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 51 comprehensive cancer centers designated by the National Cancer Institute . It has ranked as one of the nation’s top two hospitals for cancer care since the survey began in 1990, and has ranked first 15 times in the last 18 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health . Of the 16 participants, 11 are still alive, so that the median overall survival rate cannot yet be calculated.
Literally The Worst Company Ever
This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. U.S. stocks climbed on Monday, with both the S&P 500 and Nasdaq jumping more than 1% as a retreat in U.S.
The majority of the patients had also received prior abiraterone (98%) while Cabazitaxel had been used in 58% of the patients and only a quarter (28%) received enzalutamide and only 1 patient had prior radium. Results showed that of the 49 patients enrolled in the study, 33% had a response to olaparib with a median time of 40 weeks, using the composite definition defined above. Some of these responses were durable with 12 patients maintained on olaparib for more than 6 months while four patients for over a year. For the biomarker evaluations, of the 49 patients who could be evaluated for a response, 43 had fresh tumor samples while the rest had archival tissue for analysis. BRCA2 was the most commonly detected gene aberration which occurred in seven patients, of whom two had homozygous deletions, two with combined somatic and LOH , while 3 of the 7 had germline mutation with loss of the 2nd allele. ATM mutations were the 2nd most common aberrations with three of them having germline mutations with truncated ATM protein and 2 of the 3 with aberrant alleles in somatic DNA. The TOPARP study showed the beneficial utility of olaparib in a heavily pretreated population of metastatic castration-resistant prostate cancer who were biomarker-positive for aberrations in DNA repair gene.
Median overall survival was not reached; 67% of patients were alive at data cutoff. The study from Van Tine and colleagues tested ADP-A2M4 SPEAR T cells to target MAGE-A4 in 16 patients with advanced synovial sarcoma. Lymphodepletion consisted of cyclophosphamide (600 mg/m2) plus fludarabine (30 mg/m2).
It’s no longer news that Bitcoin’s dramatic fall on Thursday weighed on market sentiments relatively but Willy Woo a top crypto analyst, still believes the curtain call for Bitcoin’s overall upward rally has not occurred yet. The bitcoin price is seeing green once again after an Elon Musk-induced sell-off sent the market spiraling nearly two weeks ago.
Studies in large patient cohorts will need to clarify the clinical relevance of the different PARPi resistance mechanisms. Furthermore, research on resistance mechanisms will drive future genetic screening of resistance factors to guide therapy decisions. offers eligible public information officers paid access to a reliable news release distribution service. Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer.
Small, midsized or large, your business has unique needs, from technology to support and everything in between. Stock futures opened slightly higher Monday evening following a rally during the regular trading day, with technology stocks outperforming as concerns over rising inflation were at least temporarily pushed to the side. A lack of stats and lower trading volumes will leave the markets to fret over inflation.
Apply to SHP Choose from 12 allied health programs at School of Health Professions.GME Fellowships Learn about our graduate medical education residency and fellowship opportunities. ADP reported incorrect earnings for me with the IRS and I’ve been trying to clear this up with them for months. I can’t get in touch with anyone from ADP and the company I was working for shut down.
The trial is recruiting at various locations in North America and Europe; more information is available here. Unlike chimeric antigen receptor -modified T cells, which target surface proteins on cancer cells, TCR T-cell therapies are able to target proteins normally found inside the cell by recognising protein fragments bound to immune-related proteins on the cell surface. Objective responses in patients who were biomarker-positive were higher, with 14 of 16 patients having an 88% response with only two of the biomarker-negative having any response (6%). Similarly, radiographic responses were also more durable in the biomarker-positive patients, with a median of 9.8 months versus only 2.7 months in the biomarker-negative. There was a doubling of the overall survival to 13.8 months in the biomarker-positive group versus 7.5 months in the biomarker-negative group, all statistically significant. Unlike chimeric antigen receptor -modified T cells, which target surface proteins on cancer cells, TCR T-cell therapies are able to target proteins normally found inside the cell by recognizing protein fragments bound to immune-related proteins on the cell surface.
Your experience will vary based on your hardware, operating system, browser, internet service provider, available bandwidth, and local configuration. Some software, such as your security programs, will also affect response time. Singapore’s competition authority has approved the London Stock Exchange Group’s $27 billion acquisition of data and analytics company Refinitiv provided the bourse continues to offer certain foreign exchange benchmarks to rivals. The Competition and Consumer Commission of Singapore gave the adjusting entries conditional approval after examining whether the deal, which transforms the 300 year old bourse into a one-stop shop for data, trading and analytics, threatened competition in the currency market. Grade ≥3 AEs occurred in all patients, including lymphopenia in all patients, CRS in 88%, leukopenia in 81%, neutropenia in 81%, thrombocytopenia in 44%, anemia in 44%, and hypophosphatemia in 44%. Despite the small number of patients, the response rates compare favorably to approved agents in this setting, she said.
Patients with synovial sarcoma saw a 43.8% OR rate and a disease control rate of more than 90%. There also was an additional patient with an unconfirmed response after the data cut-off. Median duration of response in these patients was 28 weeks and median progression-free Durable Responses With Adp survival was 20 weeks. Confirmed responses were also seen in patients with lung cancer and head and neck cancer. The median duration of response was 28 weeks and 2 patients had ongoing responses beyond 72 at the time of data cutoff, September 1, 2020.
This research is part of anongoing strategic alliancebetween MD Anderson and Adaptimmune, designed to expedite the development of novel T-cell therapies for multiple cancer types. Results from this study led to a low-dose radiation sub-study, aPhase II trialof ADP-A2M4 in sarcoma and aPhase I trialof Adaptimmune’s next-generation T-cell therapy targeting MAGE-A4, ADP-A2M4CD8. In the phase 2 study, 45 patients will be assessed for the primary end point of objective response rate and the key secondary end points of safety, best overall response, time to response, DOR, progression-free survival, and overall survival. Previously during the 2020 American Society of Medical Oncology Virtual Annual Meeting, efficacy and safety findings from the ADP-A2M4 trial were presented.
“This study is a nice proof of concept for treating solid tumors and suggests there could be a role for cellular therapies in these indications going forward.” Based on the translational data from this study, induction of the IFNγ-related pathway by serum analyses was identified as an emerging biomarker of response for patients with synovial sarcoma. Additionally, the study revealed the MAGE-A4 expression and transduced cell dose were associated with reduction in tumor size. Consumer-related stocks helped tip London markets into the green, following two weeks of drops, helped by a weekend of Covid restrictions being eased. “It seems investors have had a good weekend and have realised how many other people have also been enjoying newly reinstated opportunities,” said Danni Hewson, financial analyst at AJ Bell.
The Phase I trial was designed as a dose-escalation study to assess the safety, tolerability and antitumor activity of ADP-A2M4 in patients with advanced solid tumors with expression of the MAGE-A4 protein. Patients on the trial included those with synovial sarcoma, ovarian cancer, head and neck cancer, gastric cancer, myxoid/round cell liposarcoma, non-small cell lung cancer, bladder cancer, esophageal cancer and melanoma. ThePhase I trialwas designed as a dose-escalation study to assess the safety, tolerability and antitumor activity of ADP-A2M4 in patients with advanced solid tumors with expression of the MAGE-A4 protein. Patients on the trial included those with synovial sarcoma,ovarian cancer, head and neck cancer,gastric cancer, myxoid/round cell liposarcoma, non-small cell lung cancer,bladder cancer,esophageal cancerandmelanoma. The therapy achieved strong responses in particular groups of patients in the trial.
Iran said there are still differences around the timing of when countries will return to compliance with the original 2015 nuclear agreement, allaying some concern about a rapid ramp-up in the Persian Gulf nation’s output. While the market is anticipating the Islamic Republic’s supply will pick up again by late summer, the demand recovery will be strong enough to absorb it, according to Goldman Sachs. The bank expects Brent futures to hit $80 (£57) a barrel in the next few months.
Author: Michael Cohn